{
  "meta": {
    "title": "3_Clinical_Trials_And_Miscellaneous",
    "url": "https://brainandscalpel.vercel.app/3-clinical-trials-and-miscellaneous-5a52a05a.html",
    "scrapedAt": "2025-11-30T12:34:18.048Z"
  },
  "questions": [
    {
      "text": "Pharmacovigilance refers to:",
      "choices": [
        {
          "id": 1,
          "text": "Monitoring of drug safety"
        },
        {
          "id": 2,
          "text": "Monitoring of unethical trade of drugs"
        },
        {
          "id": 3,
          "text": "Monitoring of drug potency"
        },
        {
          "id": 4,
          "text": "Monitoring of drug efficacy"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Pharmacovigilance </strong>deals with&nbsp;the<strong> monitoring of drug safety</strong>.</p>\n<p>WHO definition of pharmacovigilance:</p>\n<p>\"Science and activities related to the <strong>detection, assessment, understanding,</strong> and <strong>prevention</strong> of <strong>adverse effects</strong> or any other <strong>drug-related problems&rdquo;.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4343",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following organizations regulates the clinical trials and approval of investigational new drugs in India?",
      "choices": [
        {
          "id": 1,
          "text": "CPCSEA"
        },
        {
          "id": 2,
          "text": "CDSCO"
        },
        {
          "id": 3,
          "text": "FDA"
        },
        {
          "id": 4,
          "text": "DCGI"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Central Drug Standard Control Organisation</strong> (<strong>CDSCO</strong>)&nbsp;regulates the <strong>clinical trials</strong> and <strong>approval</strong> of <strong>investigational new drugs</strong> in India.&nbsp;</p>\n<p>The proposal for initiating trials, review of clinical trial results, and recommendations for marketing authorization is done through a committee called the <strong>Investigational New Drug</strong> (IND) <strong>Committee</strong> formed by CDSCO.&nbsp;</p>\n<p><strong>Preclinical trials</strong> are performed on<strong> animals, </strong>and they are regulated by guidelines prescribed by the&nbsp;Committee for the Purpose of the Control and Supervision of Experiments on Animals (<strong>CPCSEA) </strong>in <strong>India</strong>.</p>\n<p>The Drugs Controller General of India (<strong>DCGI</strong>) is the head of the CDSCO, under the Ministry of Health and Family Welfare in India.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4566",
      "difficulty": "medium"
    },
    {
      "text": "You are working as a research associate on clinical trials of a new drug for migraine.  What is the dose of the test drug that is usually not exceeded in phase 0 studies?",
      "choices": [
        {
          "id": 1,
          "text": "1000 mcg"
        },
        {
          "id": 2,
          "text": "1000 mg"
        },
        {
          "id": 3,
          "text": "100 mcg"
        },
        {
          "id": 4,
          "text": "100 mg"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The dose of the test drug in <strong>phase 0</strong> studies usually does not exceed <strong>100mcg.</strong> Phase 0 studies are also called&nbsp;<strong>micro-dosing studies</strong>.</p>\n<p>Very low doses of drugs, usually<strong> 1/100<sup>th</sup> </strong>of the estimated human dose or a maximum of<strong> 100 mcg </strong>is used.</p>\n<p>They are done to obtain pharmacokinetic data in humans at a very early stage of drug development. The micro-dosing stage is not mandatory and not clearly categorized by regulatory authorities yet.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4340",
      "difficulty": "medium"
    },
    {
      "text": "Good clinical practice is not required in which phase of clinical trials?",
      "choices": [
        {
          "id": 1,
          "text": "Preclinical phase"
        },
        {
          "id": 2,
          "text": "Phase 1 trial"
        },
        {
          "id": 3,
          "text": "Phase 2 trial"
        },
        {
          "id": 4,
          "text": "Phase 3 trial"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Good clinical practice is not required in the preclinical phase.</p>\n<p>Good clinical practice (<strong>GCP</strong>) is an <strong>international ethical</strong> and <strong>scientific quality standard</strong> for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials. It is primarily for the <strong>conduct</strong> of clinical <strong>trials</strong> in <strong>humans.</strong></p>\n<p><strong>Preclinical trials</strong> are performed on <strong>animals</strong> and they are regulated by guidelines prescribed by&nbsp;the&nbsp;<strong>CPCSEA</strong> (Committee for the Purpose of the Control and Supervision of Experiments on Animals)<strong>&nbsp;</strong>in<strong> India</strong>. The guidelines are laid down in good laboratory practice (<strong>GLP</strong>).</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4337",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a primary endpoint in phase 1 studies?",
      "choices": [
        {
          "id": 1,
          "text": "Safety"
        },
        {
          "id": 2,
          "text": "Tolerability"
        },
        {
          "id": 3,
          "text": "Pharmacokinetic parameters"
        },
        {
          "id": 4,
          "text": "Efficacy"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Efficacy</strong> is not a primary endpoint in phase 1 studies. <strong>Phase</strong> <strong>1</strong> studies are generally done in <strong>healthy volunteers.</strong> Efficacy can be a <strong>secondary endpoint</strong> in <strong>some studies</strong> where patients are recruited.</p>\n<p>The primary endpoints are:</p>\n<ul>\n<li>Safety</li>\n<li>Tolerability of single/multiple doses</li>\n<li>Pharmacokinetic parameters&nbsp;</li>\n</ul>\n<p>The <strong>primary</strong> endpoint denotes the <strong>purpose</strong> of the study for which it is primarily designed. The <strong>secondary</strong> endpoint denotes the measure of the valuable <strong>outcome</strong> of the study design.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4355",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following phases of  a clinical trial is also referred to as efficacy trial?",
      "choices": [
        {
          "id": 1,
          "text": "Phase 1"
        },
        {
          "id": 2,
          "text": "Phase 2"
        },
        {
          "id": 3,
          "text": "Phase 3"
        },
        {
          "id": 4,
          "text": "Phase 4"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Efficacy</strong> and <strong>appropriate dose range</strong> is the main aim of <strong>phase 2</strong> of clinical trials. It is evaluated on a small group of patients with the target disease.</p>\n<p>Phase II of clinical trials involve a <strong>small group</strong> of <strong>patients</strong> (50-500). Most of the <strong>new drugs </strong>will be administered for the<strong> first time </strong>in<strong> patients</strong> with the target disease. The study is designed to obtain <strong>proof of concept&nbsp;</strong>(potential of the drug to treat the disease) and <strong>dose-ranging study</strong> (provides input for choosing the most appropriate dose for phase 3 studies).</p>\n<p><strong>Phase 3</strong> studies are also known as <strong>pivotal</strong> studies as they establish <strong>treatment benefits.</strong></p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7210",
      "difficulty": "easy"
    },
    {
      "text": "You read a news alert that mentions a novel drug has received marketing approval for diabetes mellitus and that it has shown positive results in a pivotal trial. This corresponds to which phase of clinical trials?",
      "choices": [
        {
          "id": 1,
          "text": "Phase I"
        },
        {
          "id": 2,
          "text": "Phase II"
        },
        {
          "id": 3,
          "text": "Phase III"
        },
        {
          "id": 4,
          "text": "Phase IV"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Phase III trials </strong>are usually considered&nbsp;<strong>pivotal trials </strong>and<strong>&nbsp;</strong>are <strong>necessary for</strong> the <strong>approval</strong> of the majority of drugs.<strong>&nbsp;</strong>They<strong>&nbsp;</strong>are<strong>&nbsp;</strong>also called <strong>multi-site trials</strong> and are done for <strong>3&ndash;5 years</strong>.</p>\n<p>When the initial Phase III trials are complete, the sponsor (usually a pharmaceutical company) applies to the FDA for approval to market the drug. This application is called either a New Drug Application (NDA) or a Biologics License Application (BLA).</p>\n<p>In some drugs related to rare diseases or malignancies, phase II studies are considered as pivotal, and the drug may be approved on the basis of phase II studies.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4362",
      "difficulty": "medium"
    },
    {
      "text": "A pharmaceutical company has set up a team of physicians to oversee the Phase IV clinical trial of a new drug for SARS-CoV2 infection, to identify possible drug interactions. Which is the most appropriate statement about this phase of the clinical trial?",
      "choices": [
        {
          "id": 1,
          "text": "Done in a group of 50-500 patients"
        },
        {
          "id": 2,
          "text": "Done after a drug is approved and marketed"
        },
        {
          "id": 3,
          "text": "Done for drugs used in rare diseases"
        },
        {
          "id": 4,
          "text": "Done for formulating guidelines for therapeutic use"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Phase IV study</strong> is conducted <strong>after</strong> the<strong> drug</strong> is<strong> approved</strong> and<strong> marketed</strong>&nbsp;by regulatory authorities. It includes <strong>post-marketing surveillance</strong> and other studies that complement the earlier findings of the drug.</p>\n<p>After the drug is marketed for general use, practicing physicians are identified through whom data&nbsp;about the <strong>efficacy, acceptability,</strong> and <strong>adverse effects</strong> of the drug&nbsp;are collected on a structured proforma. Patients treated in the normal course form the study population. Therefore the study population is much larger.&nbsp;Uncommon adverse effects or those that occur only after long-term use and unsuspected drug interactions are detected at this stage.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4357",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements are true?<div class='question-desc-html'><ol>\n<li>Orphan drugs are drugs that are not used anymore.</li>\n<li>Orphan drugs are drugs for rare diseases with little commercial value for pharmaceutical companies.</li>\n<li>Orphan drugs act on orphan receptors.</li>\n<li>Orphan receptors are receptors that are discovered yet no known ligands are identified.</li>\n<li>Orphan receptors are receptors that do not serve any purpose.</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 3 and 4"
        },
        {
          "id": 2,
          "text": "2 and 4"
        },
        {
          "id": 3,
          "text": "2, 4 and 5"
        },
        {
          "id": 4,
          "text": "1, 2 and 3"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Orphan drugs</strong> are for the treatment or prevention of <strong>rare diseases</strong> with <strong>little commercial value</strong> for pharmaceutical companies. <strong>Orphan receptors</strong> are receptors that are discovered yet <strong>no known ligands are identified</strong>.</p>\n<p>There are two types of drug development. They are:</p>\n<ul>\n<li><strong>Traditional</strong> drug development: Initial drug discovery is followed by the characterization of the receptors the drugs are used to act on.</li>\n<li><strong>Contemporary</strong> drug development: Due to advances in molecular biology and genome sequencing, receptors are identified initially. The drugs are identified later using chemical screening later resulting in the discovery of orphan receptors.</li>\n</ul>\n<p>Special incentives are given by the government to pharmaceutical companies for the development and marketing of orphan drugs.</p>\n<p>Few examples of <strong>orphan drugs</strong> are:</p>\n<ul>\n<li>Liposomal amphotericin B</li>\n<li>Digoxin antibody (Digibind)</li>\n<li>Fomepizole</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4365",
      "difficulty": "easy"
    },
    {
      "text": "A pharmacologically inert substance used along with an active ingredient in a formulation is known as the:",
      "choices": [
        {
          "id": 1,
          "text": "Placebo"
        },
        {
          "id": 2,
          "text": "Nocebo"
        },
        {
          "id": 3,
          "text": "Excipient"
        },
        {
          "id": 4,
          "text": "Inducer"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>An <strong>excipient</strong> is a&nbsp;<strong>pharmacologically inert substance</strong> used along with an active ingredient in a formulation. e.g.,&nbsp;starch, lactose, FDKP</p>\n<p>Role of excipients:</p>\n<ul>\n<li>Add bulk to the active drug if used in small quantities</li>\n<li>Increase the stability of the formulation</li>\n<li>Mask unpleasant taste</li>\n</ul>\n<p>Inhaled insulin (Afrezza) consists of 2- to 2.5-&mu;m crystals of the excipient, fumaryl diketopiperazine (FDKP), that provides a large surface area for adsorption of proteins like insulin.&nbsp;&nbsp;&nbsp;</p>\n<p>Option A: <strong>Placebo</strong> is an <strong>inert substance</strong> given in the form of medication. It is generally <strong>not combined with the active ingredient</strong>.</p>\n<ul>\n<li>Endorphins may play a role in the placebo effect especially for analgesic action.</li>\n<li>It is used in the controls of clinical trials to elucidate the actual drug effect.</li>\n<li>Not all but only a few patients respond to the placebo.&nbsp;</li>\n</ul>\n<p>Option B:<strong> Nocebo </strong>is the <strong>opposite of the placebo</strong> effect where the patient experiences a negative psychodynamic effect due to their pessimistic attitude towards the medications or healthcare professionals.</p>\n<p>Option C: <strong>Inducers</strong> refer to agents that increase the expression of cytochrome enzymes involved in the metabolism of drugs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4371",
      "difficulty": "medium"
    },
    {
      "text": "Which one of the following is a placebo?",
      "choices": [
        {
          "id": 1,
          "text": "Herbal medication with no effect known"
        },
        {
          "id": 2,
          "text": "Physiotherapy"
        },
        {
          "id": 3,
          "text": "Sham surgery"
        },
        {
          "id": 4,
          "text": "Cognitive behavioural therapy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Sham surgery</strong> (<strong>placebo surgery</strong>) is a <strong>faked surgical intervention</strong> that omits the step thought to be therapeutically necessary.</p>\n<p>Note: While option A may be considered a placebo due to there being no known effects, it is not certain as to whether all possible effects (known and unknown) have been considered. Hence, weighing options A and C, the better option among the two would be C as sham surgery is a widely used placebo.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9247",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following are not reasons for the alteration of drug dosage in the elderly?",
      "choices": [
        {
          "id": 1,
          "text": "They have decreasing renal function with age"
        },
        {
          "id": 2,
          "text": "They have loss of lean body mass"
        },
        {
          "id": 3,
          "text": "They have  increased baroreceptor sensitivity"
        },
        {
          "id": 4,
          "text": "Their total body water is decreased"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The reason for the <strong>alteration</strong> of <strong>drug dosage</strong> in the <strong>elderly</strong> is&nbsp;<strong>decreased baroreceptor sensitivity</strong> due to age-related vascular stiffening.</p>\n<p>Reasons for the alteration of drug dosage in the elderly are:</p>\n<ul>\n<li>Progressive <strong>decline</strong> of <strong>renal function</strong>&nbsp;</li>\n<li>Loss of lean body mass and an <strong>increased</strong> ratio of <strong>fat</strong> to muscle, leading to an <strong>increased</strong> volume of <strong>distribution</strong> of <strong>lipophilic drugs</strong>&nbsp;</li>\n<li><strong>Decreased</strong> body <strong>water</strong> - causing&nbsp;volume of distribution (<strong>Vd</strong>) of <strong>hydrophilic drugs</strong> decreases.&nbsp;</li>\n<li>Slower absorption due to <strong>reduced gut motility.</strong></li>\n<li>Plasma albumin decreases with aging which leads to <strong>decreased</strong> plasma<strong> protein binding.</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4376",
      "difficulty": "medium"
    },
    {
      "text": "A patient started on an anti-epileptic for epilepsy developed toxic epidermal necrolysis. It was documented as a type A adverse drug reaction. Which of the following is not true regarding this adverse effect?",
      "choices": [
        {
          "id": 1,
          "text": "These reactions occur due to genetically determined abnormal reactivity to a drug."
        },
        {
          "id": 2,
          "text": "These reactions can be predicted  from the drug’s known pharmacological or toxicological effects"
        },
        {
          "id": 3,
          "text": "These reactions are generally dose-dependent"
        },
        {
          "id": 4,
          "text": "These reactions are usually common"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Type A </strong>(augmented) adverse drug reactions (ADR) are not based upon the qualitatively abnormal responses to the drug. It is based on the<strong> pharmacological properties </strong>of the drug.&nbsp;</p>\n<p>Examples of type A ADR:&nbsp;</p>\n<ul>\n<li>Side effects</li>\n<li>Toxic effects</li>\n<li>Consequences of drug withdrawal.</li>\n</ul>\n<p>They are common, reversible, and preventable.&nbsp;</p>\n<p><strong>Idiosyncrasy</strong> refers to the&nbsp;<strong>genetically</strong> determined <strong>abnormal reactivity</strong> to a drug.</p>\n<p>Adverse drug reactions can be classified into two types:</p>\n<ol class=\"enumerated\">\n<li>\n<p id=\"__p11\">Type <strong>A</strong> reactions &ndash; sometimes referred to as <strong>augmented</strong> reactions &ndash; are dose-dependent and predictable based on the pharmacology of the drug</p>\n</li>\n<li>\n<p id=\"__p12\">Type <strong>B</strong> reactions &ndash; bizarre reactions &ndash; which are <strong>idiosyncratic</strong> and not predictable on the basis of drug pharmacology. They can be based on the characteristics of patients.</p>\n</li>\n</ol>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4374",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs if taken during pregnancy can lead to this adverse effect?",
      "choices": [
        {
          "id": 1,
          "text": "Tetracycline"
        },
        {
          "id": 2,
          "text": "Thalidomide"
        },
        {
          "id": 3,
          "text": "Warfarin"
        },
        {
          "id": 4,
          "text": "Alcohol"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The baby has features suggestive of <strong>phocomelia </strong>and it results due to the consumption of <strong>thalidomide </strong>during <strong>pregnancy.</strong></p>\n<p>Phocomelia is associated with <strong>underdeveloped limbs</strong> and <strong>absent pelvic bones.</strong> Both <strong>upper</strong> and <strong>lower</strong> limbs are <strong>affected</strong> and a part of the limbs may be missing. Fused fingers and missing thumbs are also seen.</p>\n<p>Thalidomide was originally used for the treatment of <strong>pregnancy-associated morning sickness</strong> but was <strong>withdrawn</strong> due to this adverse effect.</p>\n<p>It re-entered the market for the treatment of erythema nodosum leprosum. It also has&nbsp;<span><strong>antiangiogenic</strong> and <strong>immunomodulatory</strong> effects.</span></p><hr><h3>Related Pearl: Teratogenic drugs and the birth defects</h3><table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Adverse effects</strong></td>\n</tr>\n<tr>\n<td>Penicillamine</td>\n<td>Cutis laxa syndrome</td>\n</tr>\n<tr>\n<td><strong>Lithium</strong></td>\n<td><strong>Ebstein anomaly</strong></td>\n</tr>\n<tr>\n<td>Isotretinoin</td>\n<td>Facial-ear anomalies, heart disease, CNS anomalies</td>\n</tr>\n<tr>\n<td>Progesterone</td>\n<td>Masculinization of the female fetus</td>\n</tr>\n<tr>\n<td>Quinine</td>\n<td>Abortion, thrombocytopenia, deafness</td>\n</tr>\n<tr>\n<td>Topiramate</td>\n<td>Cleft lip</td>\n</tr>\n<tr>\n<td><strong>Valproate</strong></td>\n<td>Spina bifida, limb defects, <strong>autism spectrum disorder</strong>, facial and cardiac anomalies, <strong>Coarctation of the aorta</strong>, Aortic stenosis, Pulmonary atresia, Ventricular Septal Defect. </td>\n</tr>\n<tr>\n<td><strong>Vitamin D</strong></td>\n<td><strong>Supravalvular aortic stenosis</strong></td>\n</tr>\n<tr>\n<td><strong>Warfarin</strong></td>\n<td>Fetal bleeding, <strong>hypoplastic nasal structures</strong></td>\n</tr>\n<tr>\n<td><strong>Statins</strong></td>\n<td>Vertebral, anal, cardiac, tracheoesophageal fistula, renal, arterial, limb (<strong>VACTERAL</strong>) defects</td>\n</tr>\n<tr>\n<td><strong>Phenytoin</strong></td>\n<td>Ventricular septal defect, Atrial Septal Defect, Coarctation of the aorta, Patent Ductus Arteriosus</td>\n</tr>\n<tr>\n<td>ACE inhibitors and ARBs</td>\n<td>\n<p>Hypoplasia of organs, anuria, irreversible renal failure</p>\n</td>\n</tr>\n<tr>\n<td>Carbimazole and Methimazole</td>\n<td> \n<p>Choanal atresia, aplasia cutis, tracheoesophageal fistula and fetal goiter</p>\n</td>\n</tr>\n<tr>\n<td>Alcohol</td>\n<td>Atrial Septal Defect, Ventricular Septal Defect</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/90d8d6a4f5ef49289dcafc48bbfd1efd.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4383",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following drugs can be used in the first trimester of pregnancy?",
      "choices": [
        {
          "id": 1,
          "text": "ACE inhibitors"
        },
        {
          "id": 2,
          "text": "Angiotensin receptor blockers"
        },
        {
          "id": 3,
          "text": "Propylthiouracil"
        },
        {
          "id": 4,
          "text": "Statins"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Propylthiouracil</strong>&nbsp;can be used in the <strong>first trimester</strong> of pregnancy. It is indicated in the management of<strong> hyperthyroidism.</strong></p><hr><h3>Related Pearl: Teratogenic drugs and the birth defects</h3><table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Adverse effects</strong></td>\n</tr>\n<tr>\n<td>Penicillamine</td>\n<td>Cutis laxa syndrome</td>\n</tr>\n<tr>\n<td><strong>Lithium</strong></td>\n<td><strong>Ebstein anomaly</strong></td>\n</tr>\n<tr>\n<td>Isotretinoin</td>\n<td>Facial-ear anomalies, heart disease, CNS anomalies</td>\n</tr>\n<tr>\n<td>Progesterone</td>\n<td>Masculinization of the female fetus</td>\n</tr>\n<tr>\n<td>Quinine</td>\n<td>Abortion, thrombocytopenia, deafness</td>\n</tr>\n<tr>\n<td>Topiramate</td>\n<td>Cleft lip</td>\n</tr>\n<tr>\n<td><strong>Valproate</strong></td>\n<td>Spina bifida, limb defects, <strong>autism spectrum disorder</strong>, facial and cardiac anomalies, <strong>Coarctation of the aorta</strong>, Aortic stenosis, Pulmonary atresia, Ventricular Septal Defect. </td>\n</tr>\n<tr>\n<td><strong>Vitamin D</strong></td>\n<td><strong>Supravalvular aortic stenosis</strong></td>\n</tr>\n<tr>\n<td><strong>Warfarin</strong></td>\n<td>Fetal bleeding, <strong>hypoplastic nasal structures</strong></td>\n</tr>\n<tr>\n<td><strong>Statins</strong></td>\n<td>Vertebral, anal, cardiac, tracheoesophageal fistula, renal, arterial, limb (<strong>VACTERAL</strong>) defects</td>\n</tr>\n<tr>\n<td><strong>Phenytoin</strong></td>\n<td>Ventricular septal defect, Atrial Septal Defect, Coarctation of the aorta, Patent Ductus Arteriosus</td>\n</tr>\n<tr>\n<td>ACE inhibitors and ARBs</td>\n<td>\n<p>Hypoplasia of organs, anuria, irreversible renal failure</p>\n</td>\n</tr>\n<tr>\n<td>Carbimazole and Methimazole</td>\n<td> \n<p>Choanal atresia, aplasia cutis, tracheoesophageal fistula and fetal goiter</p>\n</td>\n</tr>\n<tr>\n<td>Alcohol</td>\n<td>Atrial Septal Defect, Ventricular Septal Defect</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4385",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following drugs cannot cross the placenta and can safely be used in a pregnant woman?",
      "choices": [
        {
          "id": 1,
          "text": "Phenytoin"
        },
        {
          "id": 2,
          "text": "Diazepam"
        },
        {
          "id": 3,
          "text": "Morphine"
        },
        {
          "id": 4,
          "text": "Heparin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Heparin</strong>&nbsp;is a <strong>large molecule</strong> and <strong>cannot cross</strong> the <strong>placenta.</strong> Hence, heparin can be used safely in a pregnant woman.</p>\n<p>Unfractionated or low molecular weight heparin is the <strong>preferred anticoagulant</strong> in <strong>pregnancy.</strong></p>\n<p>Option A: Phenytoin crosses the placenta and can cause fetal hydantoin syndrome.&nbsp;</p>\n<p>Options B and C: Diazepam and morphine are lipophilic molecules and can cross the placenta.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4387",
      "difficulty": "medium"
    },
    {
      "text": "'Me-too drugs' do not differ significantly in which of the following pharmacological features as compared to the prototypical drug?",
      "choices": [
        {
          "id": 1,
          "text": "Absorption"
        },
        {
          "id": 2,
          "text": "Metabolism"
        },
        {
          "id": 3,
          "text": "Mechanism of action"
        },
        {
          "id": 4,
          "text": "Elimination"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Me-too drugs </strong>are <strong>chemically related</strong> to the prototype<strong>&nbsp;</strong>or other chemical compounds that have an <strong>identical mechanism of action.&nbsp;</strong></p>\n<p>Various statins present in the market can be considered as \"Me-too drugs\". The pharmacokinetic parameters (absorption, distribution, metabolism, and elimination) vary significantly between them (atorvastatin and rosuvastatin have a very long duration of action), but the core mechanism of action remains the same: HMG CoA reductase inhibition and decrease in cholesterol synthesis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4564",
      "difficulty": "medium"
    },
    {
      "text": "As a medical officer in a PHC, you anticipate a rise in infections following the worsening flood in your area. You write a letter to the district collector requesting to provide an additional supply of essential medicines. Which of the following best describes these medicines?",
      "choices": [
        {
          "id": 1,
          "text": "These are drugs needed to treat emergency conditions"
        },
        {
          "id": 2,
          "text": "These are drugs needed to treat serious diseases"
        },
        {
          "id": 3,
          "text": "These are drugs that  satisfy the priority health needs of the population"
        },
        {
          "id": 4,
          "text": "These are drugs that have been in use for a long time"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Essential medicines </strong>are those medicines that <strong>satisfy</strong> the <strong>priority health care needs</strong> of the population.</p>\n<p>They are selected with due regard to:&nbsp;</p>\n<ul>\n<li>Public health relevance</li>\n<li>Evidence on efficacy and safety</li>\n<li>Comparative cost-effectiveness</li>\n</ul>\n<p>WHO publishes a model list of essential medicines that provides a framework for individual nations to draw their own national list.&nbsp;The<strong> 21<sup>st</sup></strong>&nbsp;<strong>Essential Medicines List</strong>, published in April 2019 brings the total to<strong> 460&nbsp;drugs</strong> deemed essential for addressing the most important public health needs globally.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4571",
      "difficulty": "easy"
    },
    {
      "text": "The schedule that deals with prescription drugs under the Drugs and Cosmetics Act is ______.",
      "choices": [
        {
          "id": 1,
          "text": "Schedule P"
        },
        {
          "id": 2,
          "text": "Schedule H"
        },
        {
          "id": 3,
          "text": "Schedule Y"
        },
        {
          "id": 4,
          "text": "Schedule  D"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Schedule H</strong> deals with<strong> prescription drugs.</strong> All the drugs listed under schedule H should be provided to the patient only with the&nbsp;<strong>prescription</strong> from a registered medical practitioner.&nbsp;</p>\n<p>All the drugs under the list must have the warning mentioned below, on their packaging listed prominently.&nbsp;</p>\n<p><em>\"Schedule H drug. Warning: To be sold by retail on the prescription of a registered medical practitioner only\"</em>&nbsp;</p>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p><strong>Schedule H1</strong>: To be sold on the production of a <strong>valid prescription,</strong> but the chemist will maintain a separate register where the identity of the patient, contact details of the prescribing doctor, and the name and dispensed quantity of the drug will be recorded. The dispensing <strong>quantity</strong> should be <strong>strictly</strong> according to the valid prescription. It&nbsp;is a recently introduced list with the objective of <strong>curtailing indiscriminate use</strong> of<strong> antimicrobials</strong>.&nbsp;</p>\n<p><strong>Schedule X:</strong>&nbsp;To be sold with a valid prescription. Prescription in duplicate, separate license requirements, meticulous storage, and dispensing records must be maintained by the chemist. The drugs that have <strong>high abuse liability</strong> are included in schedule X.</p>\n</div>\n</div>\n<p>&nbsp;</p><hr><h3>Related Pearl: Drug regulatory schedules 1940: (2016 update)</h3><table>\n<tbody>\n<tr>\n<td><strong>Schedule</strong></td>\n<td><strong>Details</strong></td>\n</tr>\n<tr>\n<td>Schedule C</td>\n<td><strong>Biological</strong> and other special products e.g. <strong>Toxins, Insulin, Sera &amp; Antibiotics</strong>.</td>\n</tr>\n<tr>\n<td>Schedule D</td>\n<td>List of drugs <strong>exempted from the provision of import</strong> of drugs.</td>\n</tr>\n<tr>\n<td>Schedule F</td>\n<td>\n<p><strong>Blood</strong> and blood products</p>\n<p>F I - Production of Bacterial <strong>vaccines, Anti- Sera</strong></p>\n<p>F II - Specification of standards for <strong>Surgical dressing</strong></p>\n<p>FF- Specification of standard <strong>Ophthalmic</strong> preparation</p>\n</td>\n</tr>\n<tr>\n<td>Schedule G</td>\n<td>With a label of <strong>Caution, dangerous</strong> to use except under <strong>medical supervision</strong>.</td>\n</tr>\n<tr>\n<td>Schedule H</td>\n<td><strong>Prescription</strong> drugs.</td>\n</tr>\n<tr>\n<td>Schedule J</td>\n<td>List of diseases that a drug may not prevent or cure. Eg - <strong>HIV &amp; Atherosclerosis</strong></td>\n</tr>\n<tr>\n<td>Schedule M</td>\n<td>Regulations regarding good manufacturing practices</td>\n</tr>\n<tr>\n<td>Schedule P</td>\n<td>Regulations regarding&nbsp;the <strong>life period</strong> and storage of various drugs.</td>\n</tr>\n<tr>\n<td>Schedule W</td>\n<td>Drugs marketed under <strong>generic</strong> names.</td>\n</tr>\n<tr>\n<td>Schedule X</td>\n<td>Drugs having <strong>abuse</strong> and dependence liability.</td>\n</tr>\n<tr>\n<td>Schedule Y</td>\n<td>Requirement and guidelines for<strong> import/ manufacture or Clinical trials</strong> in India</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4588",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is a schedule X drug?",
      "choices": [
        {
          "id": 1,
          "text": "Halothane"
        },
        {
          "id": 2,
          "text": "Thalidomide"
        },
        {
          "id": 3,
          "text": "Ketamine"
        },
        {
          "id": 4,
          "text": "Colistin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ketamine</strong> is a schedule X drug.&nbsp;</p>\n<p>According to The Drugs and Cosmetics Act-1945,</p>\n<p><strong>Schedule X drugs</strong> are those that have<strong>&nbsp;high abuse liability </strong>and are&nbsp;to be sold with a valid<strong> prescription only.</strong></p>\n<p>A prescription in duplicate, separate license requirement, meticulous storage, and dispensing records must be maintained by the chemist.</p>\n<p>Option B: Thalidomide is a schedule H drug.&nbsp;</p>\n<p>Option D: Colistin is a schedule P drug.</p><hr><h3>Related Pearl: Drug regulatory schedules 1940: (2016 update)</h3><table>\n<tbody>\n<tr>\n<td><strong>Schedule</strong></td>\n<td><strong>Details</strong></td>\n</tr>\n<tr>\n<td>Schedule C</td>\n<td><strong>Biological</strong> and other special products e.g. <strong>Toxins, Insulin, Sera &amp; Antibiotics</strong>.</td>\n</tr>\n<tr>\n<td>Schedule D</td>\n<td>List of drugs <strong>exempted from the provision of import</strong> of drugs.</td>\n</tr>\n<tr>\n<td>Schedule F</td>\n<td>\n<p><strong>Blood</strong> and blood products</p>\n<p>F I - Production of Bacterial <strong>vaccines, Anti- Sera</strong></p>\n<p>F II - Specification of standards for <strong>Surgical dressing</strong></p>\n<p>FF- Specification of standard <strong>Ophthalmic</strong> preparation</p>\n</td>\n</tr>\n<tr>\n<td>Schedule G</td>\n<td>With a label of <strong>Caution, dangerous</strong> to use except under <strong>medical supervision</strong>.</td>\n</tr>\n<tr>\n<td>Schedule H</td>\n<td><strong>Prescription</strong> drugs.</td>\n</tr>\n<tr>\n<td>Schedule J</td>\n<td>List of diseases that a drug may not prevent or cure. Eg - <strong>HIV &amp; Atherosclerosis</strong></td>\n</tr>\n<tr>\n<td>Schedule M</td>\n<td>Regulations regarding good manufacturing practices</td>\n</tr>\n<tr>\n<td>Schedule P</td>\n<td>Regulations regarding&nbsp;the <strong>life period</strong> and storage of various drugs.</td>\n</tr>\n<tr>\n<td>Schedule W</td>\n<td>Drugs marketed under <strong>generic</strong> names.</td>\n</tr>\n<tr>\n<td>Schedule X</td>\n<td>Drugs having <strong>abuse</strong> and dependence liability.</td>\n</tr>\n<tr>\n<td>Schedule Y</td>\n<td>Requirement and guidelines for<strong> import/ manufacture or Clinical trials</strong> in India</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0127",
      "difficulty": "medium"
    },
    {
      "text": "A first-year resident administers an intramuscular injection to a patient by the Z track technique. What is the advantage of this technique?",
      "choices": [
        {
          "id": 1,
          "text": "Increase absorption rate"
        },
        {
          "id": 2,
          "text": "Prevent staining of skin"
        },
        {
          "id": 3,
          "text": "Reduce allergic manifestations"
        },
        {
          "id": 4,
          "text": "Longer duration of action"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The advantage of the<strong>&nbsp;'Z-track technique'&nbsp;</strong>for intramuscular administration is that it<strong> prevents skin staining.&nbsp;</strong></p>\n<p>Z-track technique procedure:&nbsp;</p>\n<ol>\n<li>Stretch the skin by pulling it laterally away from the intended point of injection.</li>\n<li>Insert the needle into the site at a 90˚ angle, aspirate by pulling back to see if the needle has a penetrated vessel.</li>\n<li>If blood is aspirated withdraw the needle, and repeat the procedure at another site with new equipment and medication.</li>\n<li>If no blood is aspirated administer the injection.</li>\n<li>Wait for 10 seconds and then withdraw the needle, and release the skin allowing the displaced tissue to seal the needle track.</li>\n</ol>\n<p><strong>Advantages:</strong>&nbsp;</p>\n<ul>\n<li>The 'Z-track'&nbsp;<strong>prevents leakage</strong> of the medication into the subcutaneous tissue and<strong> skin staining </strong>through the tract to the surface of the skin</li>\n<li><strong>Pain intensity </strong>is also<strong> reduced</strong>&nbsp;</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/23b7eb6ea07e4ccd8689c15d21f4d601x1280x2717.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4586",
      "difficulty": "medium"
    },
    {
      "text": "Z track technique is used for?",
      "choices": [
        {
          "id": 1,
          "text": "Administration of nicotine patches"
        },
        {
          "id": 2,
          "text": "Monitoring of carbamazepine therapy"
        },
        {
          "id": 3,
          "text": "Administration of long acting depot antipsychotics"
        },
        {
          "id": 4,
          "text": "Monitoring of lithium therapy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong> Z-track technique</strong>&nbsp;is used for the intramuscular administration of <strong>long-acting depot antipsychotics.</strong></p>\n<p><strong>Advantages:</strong>&nbsp;</p>\n<ul>\n<li>The 'Z-track'&nbsp;prevents leakage&nbsp;of the medication into the subcutaneous tissue and&nbsp;skin staining&nbsp;through the tract to the surface of the skin</li>\n<li>Pain intensity&nbsp;is also&nbsp;reduced&nbsp;</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/95f332d3004e48e6a476a371eecd59f0x1280x2717.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0138",
      "difficulty": "easy"
    },
    {
      "text": "A drug label suggests storage in a 'cool' place. What is the temperature at which this drug is to be stored?",
      "choices": [
        {
          "id": 1,
          "text": "- 2 degree Celsius"
        },
        {
          "id": 2,
          "text": "0 degree Celsius"
        },
        {
          "id": 3,
          "text": "2-6 degree Celsius"
        },
        {
          "id": 4,
          "text": "8-15 degree Celsius"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Storing</strong> at a <strong>cool</strong> place means to store at <strong>8-15 degrees</strong> <strong>C</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Label instructions </strong></td>\n<td><strong>Temperature</strong></td>\n</tr>\n<tr>\n<td>Store frozen&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</td>\n<td>-20<sup>o</sup>&nbsp;C</td>\n</tr>\n<tr>\n<td>Keep cool&nbsp;</td>\n<td>&nbsp;8-15<sup>o</sup>&nbsp;C</td>\n</tr>\n<tr>\n<td>Store at room temperature&nbsp;</td>\n<td>15-25<sup>o</sup>&nbsp;C</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Examples for drugs to be stored under cool temperature include insulin, nicorandil.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7107",
      "difficulty": "medium"
    }
  ]
}